How informative is the immune response against surrogate tumor antigens to assess antitumor immunity?

Frontiers in Oncology

Volumn 4 JUN, Issue , 2014, Pages

  Janelle, Valérie ^a,b   Lamarre, Alain ^a,b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

B16F10; CD8 positive T lymphocytes; Oncolytic viruses; Tumor antigens; VSV

Indexed keywords

CD1D ANTIGEN; CD8 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 100; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOLYTIC VIRUS; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 1;

ANTIGEN PRESENTATION; ARTICLE; CANCER CONTROL; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOPOTENTIATION; LIVER CANCER; MYELOID DENDRITIC CELL; NATURAL KILLER T CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; UPREGULATION; VESICULAR STOMATITIS VIRUS;

EID: 84904699186     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00135     Document Type: Article

References (12)

1. Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev (2010) 21(2-3):127-34. doi:10.1016/j.cytogfr.2010.02.014
2. Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, et al. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther (2010) 17(2):158-70. doi:10.1038/gt.2009.161
3. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 20(10):1119-32. doi:10.1089/hum.2009.135
4. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 9(9):1163-76. doi:10.1517/14712590903170653
5. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 67(6):2840-8. doi:10.1158/0008-5472.CAN-06-3974
6. Janelle V, Brassard F, Lapierre P, Lamarre A, Poliquin L. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. J Virol (2011) 85(13):6513-20. doi:10.1128/JVI.02484-10
7. Prevost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol (1998) 161(5):2187-94.
8. Janelle V, Langlois M-P, Lapierre P, Charpentier T, Poliquin L, Lamarre A. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control. Mol Ther (2014). doi:10.1038/mt.2014.34
9. Calabi F, Bradbury A. The CD1 system. Tissue Antigens (1991) 37(1):1-9. doi:10.1111/j.1399-0039.1991.tb01836.x
10. Brutkiewicz RR, Bennink JR, Yewdell JW, Bendelac A. TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1. J Exp Med (1995) 182(6):1913-9. doi:10.1084/jem.182.6.1913
11. Renukaradhya GJ, Khan MA, Shaji D, Brutkiewicz RR. Vesicular stomatitis virus matrix protein impairs CD1d-mediated antigen presentation through activation of the p38 MAPK pathway. J Virol (2008) 82(24):12535-42. doi:10.1128/JVI.00881-08
12. Pedersen SR, Sørensen MR, Buus S, Christensen JP, Thomsen AR. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. J Immunol (2013) 191(7):3955-67. doi:10.4049/jimmunol.1300555